Renal Cancer - Results from #60

Primary tumor ablation in metastatic renal cell carcinoma. November 15, 2024

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors. November 15, 2024

Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma. November 14, 2024

Urine leak and vascular complications following robotic partial nephrectomy: a contemporary single-center experience. November 14, 2024

A National Study of the Rate of Benign Pathology After Partial Nephrectomy for T1 Renal Cell Carcinoma: Should We Be Satisfied? November 13, 2024

Multiarm, non-randomised, single-centre feasibility study-investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol. November 13, 2024

Volumetric body composition analysis of the Cancer Genome Atlas reveals novel body composition traits and molecular markers Associated with Renal Carcinoma outcomes. November 12, 2024

High RRM2 Correlates with Mitochondrial and Immune Responses in the Eosinophilic Subtype of Clear Cell Renal Cell Carcinoma. November 12, 2024

Comprehensive assessment of the association between tumor-infiltrating immune cells and the prognosis of renal cell carcinoma. November 11, 2024

Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study. November 11, 2024

First and Second-line Treatments in Metastatic Renal Cell Carcinoma. November 8, 2024

Investigation of intrafractional spinal cord and spinal canal movement during stereotactic MR-guided online adaptive radiotherapy for kidney cancer. November 8, 2024

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting. November 7, 2024

C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer. November 7, 2024

Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review. November 6, 2024

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors. November 6, 2024

Kidney cancer following occupational exposure to trichloroethylene: clinical case series and review of the literature. November 5, 2024

NODESAFE Nomogram: A Novel Score System to Predict Lymph Node Involvement at the Time of Nephrectomy or Nodal Recurrence in Nonmetastatic Renal Cell Carcinoma. November 5, 2024

Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy November 4, 2024

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients. November 4, 2024

Page 4 of 457